About Inflammatix
Inflammatix is a Healthcare company based in San Francisco (United States) founded in 2016. Provider of diagnostic solutions for systemic infections. Inflammatix has raised $191.47 million across 13 funding rounds from investors including NIH, Khosla Ventures and HHS. The company has 54 employees. Inflammatix offers products and services including TriVerity Test and Host Response Dx. Its focus areas include Life Sciences, Clinical Genomics, Hybridization Based and Microarrays. Its competitors include Karius, Visby Medical and Agendia; 3 of its 3 listed competitors have raised funding.
Company details
Inflammatix was founded in 2016 and is headquartered in San Francisco, United States. Operations focus on the health technology sector, where proprietary technology derived from Stanford University research is utilized. Gene expression patterns in the immune system are measured to diagnose sepsis and acute infections. Products offered include InSep for sepsis testing, ViraBac for infection differentiation, and SARS-CoV-2 swab tests.
- Headquarters San Francisco, United States
- Employees 54
- SectorsHealthcare
- Email••••••••
- Website inflammatix.com
- Social LinkedIn X
- Total Equity Funding$191.47M (USD)
in 13 rounds
- Latest Funding Round$57M (USD), Series E
Sep 2024
- InvestorsNIH
& 13 more
- Employee Count54
Products & Services of Inflammatix
Inflammatix offers a comprehensive portfolio of products and services, including TriVerity Test and Host Response Dx.
Analyzes immune responses to identify infections and predict severity.
Measures immune signatures for detecting and managing acute infections.
Funding Insights of Inflammatix
Inflammatix has successfully raised a total of $191.47M across 13 strategic funding rounds. The most recent funding activity was a Series E round of $57 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $191.47M
- Total Rounds 13
- Last Round Series E — $57M
- Investors Count 14
Latest 10 of 13 funding rounds of Inflammatix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $57M | Series E | – | Think.Health, Khosla Ventures | |
| Jul 2023 | $299,762 | Grant | – | – | |
| Nov 2021 | $12.1M | Grant | – | – | |
| Nov 2021 | $1.7M | Grant | – | – | |
| Aug 2021 | $1.7M | Grant | – | – | |
| Mar 2021 | $102.4M | Series D | – | – | |
| Jan 2021 | $251,371 | Grant | – | – | |
| Nov 2020 | $7.4M | Grant | – | – | |
| Sep 2020 | $1.1M | Grant | – | – | |
| Jan 2020 | $32.07M | Series C | – | Grey Sky Venture Partners |
14 investors in total: 14 institutional.
Investors in Inflammatix
Inflammatix has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, Khosla Ventures and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage tech & life sciences focused VC firm investing in geographies such as Europe | think-health.de | Furstenfeldbruck, Germany | ||
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Venture capital firm investing in life sciences & tech sectors | npv.vc | Cambridge, United States | ||
Iberis Capital is recognized as a leading private equity and venture capital manager in Portugal. | 2017 | iberiscapital.com | Lisbon, Portugal | |
Life sciences-focused VC firm investing in Europe and Canada | 2007 | vesaliusbiocapital.com | Strassen, Luxembourg | |
Raw Ventures is engaged in funding innovative technology startups. | rawventures.com | London, United Kingdom | ||
Private equity and hedge fund focused on consumer, business services, financial, healthcare, and multiple sectors | d1capital.com | New York, United States | ||
| gsvp.com | ||||
Startups are accelerated by Stanford-backed program in Palo Alto. | startx.com | Palo Alto, United States | ||
Standalone pediatric hospital services are provided in Peoria. | 1877 | osfhealthcare.org | Peoria, United States |
Investor details for Inflammatix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Inflammatix
43 people are tracked at Inflammatix (16 in leadership, 9 in board & advisors, 18 in team); the tracked headcount is 54.
| Name | Role | Group |
|---|---|---|
Oliver Liesenfeld | Chief Medical Officer | Leadership |
Ljubomir Buturovic | VP of Machine Learning | Leadership |
Diana Lane | VP, Quality Assurance & Regulatory Affairs | Leadership |
Paul Fleming | VP of Engineering | Leadership |
Tim Sweeney | Co-Founder & CEO | Leadership |
Ambika Srinath | Director, Systems Engineering And Design Assurance | Leadership |
Jean Lee | Talent Acquisition Partner | Leadership |
Tracie Brack | Head Of Talent Acquisition (fractional) | Leadership |
Jamie Lewis | Chief Commercial Officer | Leadership |
Purvesh Khatri | Co-Founder & Chief Scientific Officer | Leadership |
Tawny Darling | VP, People Operations | Leadership |
Jean-Claude Gerard | VP, Commercial Operations for EMEA | Leadership |
Christopher MacGriff | VP, Strategy & Corporate Development | Leadership |
Jennee DeVore | VP, Legal | Leadership |
Natalie N. Whitfield | Senior Director Of Medical Affairs | Leadership |
Joao Fonseca | CTO | Leadership |
Jim Ducharme | Advisor | Board & advisors |
Nathan A Ledeboer | Advisor | Board & advisors |
Jesus F Bermejo-Martin | Advisor | Board & advisors |
Hector R. Wong | Advisor | Board & advisors |
23 more people are available in the full profile.
Complete people profiles for Inflammatix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Inflammatix
3 dated milestones of Inflammatix across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Inflammatix is founded.
- Funding First funding round.
- Funding Latest funding round, Series E, of $57.0M.
Competitors of Inflammatix
Inflammatix has 3 listed competitors in our database, 3 of them funded. They include Karius, Visby Medical and Agendia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. | |
| agendia.com | 2003 | Irvine, United States | $123M | 203 | Genomic diagnostic products for cancer treatment are provided. |
Detailed competitors of Inflammatix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Inflammatix
The website of Inflammatix (inflammatix.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▼ 16.8% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Inflammatix (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inflammatix
Complete news archive for Inflammatix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inflammatix
Inflammatix was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Inflammatix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Inflammatix is a funded company, having raised a total of $191.47M across 13 funding rounds to date. The company's 1st funding round was a Series C of $32.07M, raised on May 2017.
Inflammatix has 54 employees.
Inflammatix was founded in 2016 and is headquartered in San Francisco, United States. Operations focus on the health technology sector, where proprietary technology derived from Stanford University research is utilized. Gene expression patterns in the immune system are measured to diagnose sepsis and acute infections. Products offered include InSep for sepsis testing, ViraBac for infection differentiation, and SARS-CoV-2 swab tests.
Inflammatix's top competitors include Visby Medical, Agendia and Karius.
Inflammatix offers TriVerity Test and Host Response Dx.
Inflammatix has 14 investors. Key investors include NIH, Khosla Ventures, HHS, DARPA, and OSF HealthCare.